Guardant Health, Inc. (GH) Revenue by Segment
Guardant Health revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Guardant Health's largest product or service was Oncology, with $219.11 million or 65% of revenue, up 38.1% from a year earlier. Next: Biopharma & Data (18%), Screening (16%) and Licensing & Other (1%).
By region, United States brought in 95% and Non-US brought in 5% of revenue in Q2 fiscal 2026.
By country, UNITED STATES brought in 95% and Non-US brought in 5% of revenue in Q2 fiscal 2026.
The fastest-growing product or service from a year earlier was Screening (+256.9%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
Guardant Health, Inc.
Revenue breakdown
Fiscal quarters, from company filings
Guardant Health revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Oncology | $219.1M | $205.0M | $184.4M | $158.7M | 65% |
| Biopharma & Data | $60.9M | $53.0M | $54.7M | $56.0M | 18% |
| Screening | $52.9M | $41.6M | $24.1M | $14.8M | 16% |
| Licensing & Other | $2.1M | $2.1M | $2.0M | $2.6M | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Guardant Health revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $318.0M | $284.6M | $249.4M | $216.7M | 95% |
| Non-US | $16.9M | $17.0M | $15.8M | $15.4M | 5% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Guardant Health revenue by country, last 4 quarters
| Country | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| UNITED STATES | $318.0M | $284.6M | $249.4M | $216.7M | 95% |
| Non-US | $16.9M | $17.0M | $15.8M | $15.4M | 5% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Guardant Health?
Oncology: $219.11 million, or 65% of revenue, in Q2 fiscal 2026.
What are Guardant Health's main products and services?
By revenue in Q2 fiscal 2026: Oncology (65%), Biopharma & Data (18%), Screening (16%) and Licensing & Other (1%).
Where does Guardant Health make its money?
By region in Q2 fiscal 2026: United States (95%) and Non-US (5%).
